Health Technology Assessment Policy and Methods Review

Under the 2022-27 Strategic Agreement with Medicines Australia (Strategic Agreement) we will support and resource a Health Technology Assessment (HTA) Policy and Methods Review (Review).


Under the Strategic Agreement, the Australian Government and Medicines Australia have the shared goals of: 

  • reducing time to access to health technologies for Australian patients so that they can access new health technologies as early as possible
  • building on Australia’s status as a world leader in providing patients access to affordable healthcare. 

To achieve these goals, we will ensure that:

  • our assessment processes keep pace with rapid advances in health technology
  • barriers to access are minimised. 

HTA Review Reference Committee

The HTA Review is being overseen by a Reference Committee. The membership of the Reference Committee is as follows:

  • Independent Chair: Adjunct Professor Debora Picone AO
  • Patient Representatives: Ms Ann Single and Dr Dawn Casey PSM
  • Chair of the Pharmaceutical Benefits Advisory Committee (PBAC): Professor Andrew Wilson
  • Clinical/Scientific Representative: Professor Andrew Roberts AM
  • Industry Representative: Mr John Young
  • Government Nominee: Ms Adriana Platona PSM

The HTA Review Reference Committee will:

  • agree the terms of reference for the HTA Review
  • agree the expert in HTA to support the HTA Review
  • oversee public consultations and considering submissions to the HTA Review
  • oversee the analysis undertaken by the expert in HTA
  • prepare a final review report and recommendations.

Terms of reference for the HTA Review

The HTA Review Reference Committee prepared a draft terms of reference and sought feedback from organisations representing:

  • patients
  • consumers
  • industry
  • advisory bodies
  • Commonwealth and state and territory governments.

The list of stakeholders that the HTA Review Reference Committee sought feedback from is available in the communique for the Committee’s 1 December 2022 and 19 December 2022 meetings.

The reference committee will consider the feedback received on the draft terms of reference at its 27 January 2023 meeting.

Once the terms of reference is finalised, we will open public consultations on the HTA Review, including requests for submissions, on the Office of Health Technology Assessment Consultation Hub.

Strategic Agreements with the Medicines Industry

The HTA Review is one of the key commitments in the Strategic Agreement.

The Strategic Agreement includes commitments to several reforms and reform processes which ensure that Australians can:

  • access break-through new medicines as early as possible
  • deliver a robust and uninterrupted supply of the medicines Australians use every day.


Learn more

To learn more about the Strategic Agreement with Medicines Australia, see the PBS website

If you have any questions about the HTA Policy and Methods Review, see our frequently asked questions


HTA Review Secretariat

Contact for the Health Technology Assessment Review
Last updated:

Help us improve

If you would like a response please use the enquiries form instead.